| 17β-estradiol | Estrace | Pill | Moderate to severe vasomotor symptoms; moderate to severe symptoms of vulvar and vaginal atrophy; hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; prevention of osteoporosis | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; Active or recent (e.g., within the past year) arterial thromboembolic disease; Known sensitivity to FD&C Yellow No. 5 (tartrazine) |
| 17β-estradiol | Alora | Patch | Moderate to severe vasomotor symptoms; moderate to severe symptoms of vulvar and vaginal atrophy; hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; prevention of osteoporosis | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; Active or recent (e.g., within the past year) arterial thromboembolic disease; Known hypersensitivity to product or its ingredients |
| 17β-estradiol | Climara | Patch | Moderate to severe vasomotor symptoms; moderate to severe symptoms of vulvar and vaginal atrophy; hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; prevention of osteoporosis | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; Active or history of arterial thromboembolic disease; High risk of venous thrombosis or arterial thrombosis; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders |
| 17β-estradiol | Vivelle-Dot | Patch | Moderate to severe vasomotor symptoms; moderate to severe symptoms of vulvar and vaginal atrophy; hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; prevention of osteoporosis | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Known hypersensitivity to product or its ingredients |
| 17β-estradiol | Minivelle | Patch | Moderate to severe vasomotor symptoms; prevention of osteoporosis | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Known hypersensitivity to product or its ingredients |
| 17β-estradiol | Menostar | Patch | Prevention of osteoporosis | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders |
| 17β-estradiol | Estrogel | Gel | Moderate to severe vasomotor symptoms; moderate to severe symptoms of vulvar and vaginal atrophy | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Anaphylactic reaction or angioedema with product |
| 17β-estradiol | Elestrin | Gel | Moderate to severe vasomotor symptoms | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Anaphylactic reaction or angioedema with product |
| 17β-estradiol | Divigel | Gel | Moderate to severe vasomotor symptoms | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Known hypersensitivity to product or its ingredients; Anaphylactic reaction or angioedema with product |
| 17β-estradiol | Estrace | Vaginal cream | Moderate to severe vulvar and vaginal atrophy due to menopause | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Anaphylactic reaction or angioedema with product |
| 17β-estradiol | Estring | Vaginal ring | Moderate to severe vulvar and vaginal atrophy due to menopause | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Known hypersensitivity to product or its ingredients; Anaphylactic reaction or angioedema with product |
| 17β-estradiol | Evamist | Spray | Moderate to severe vasomotor symptoms | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Anaphylactic reaction or angioedema with product |
| 17β-estradiol | Imvexxy | Vaginal tablet | Moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Anaphylactic reaction or angioedema with product |
| Estradiol cypionate | Depo-estradiol | Injection | Moderate to severe vasomotor symptoms; hypoestrogenism due to hypogonadism | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; Recent (e.g., within the past year) arterial thromboembolic disease; Known hypersensitivity to product or its ingredients |
| Micronized progesterone | Prometrium | Pill | Prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets; also indicated for use in secondary amenorrhea | History of arterial thromboembolic disease; Undiagnosed abnormal genital bleeding; Known, suspected, or history of cancer of the breast; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease |
| Micronized progesterone | Crinone | Vaginal gel | Supplementation or replacement as part of an assisted reproductive technology (ART) treatment for infertile women with progesterone deficiency (8%); secondary amenorrhea (4% and 8%) | Undiagnosed vaginal bleeding; Liver dysfunction or disease; Known or suspected malignancy of the breast or genital organs; Missed abortion; Known sensitivity or hypersensitivity to product or its ingredients |
| Micronized progesterone | Prochieve | Vaginal gel | Supplementation or replacement as part of an assisted reproductive technology (ART) treatment for infertile women with progesterone deficiency (8%); secondary amenorrhea (4% and 8%) | Undiagnosed vaginal bleeding; Liver dysfunction or disease; Known or suspected malignancy of the breast or genital organs; Missed abortion; Known sensitivity or hypersensitivity to product or its ingredients |
| Micronized progesterone | Endometrin | Ovules | To support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (ART) treatment program for infertile women | History of arterial thromboembolic disease; Known allergic reaction; Undiagnosed vaginal bleeding; Liver dysfunction or disease; History of arterial thromboembolic disease; Known or suspected malignancy of the breast or genital organs; Ectopic pregnancy or missed abortion; Known allergic reactions |
| 17β-estradiol and micronized progesterone | Bijuva | Pill | Moderate to severe vasomotor symptoms due to menopause | Undiagnosed vaginal bleeding; Known, suspected, or history of breast cancer; Known or suspected estrogen-dependent neoplasia; Active deep vein thrombosis, pulmonary embolism, or history of these conditions; Liver dysfunction or disease; Known or suspected pregnancy; History of arterial thromboembolic disease; Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; Known hypersensitivity to product or its ingredients; Anaphylactic reaction or angioedema with product |
| Testosterone | Testim | Gel | Indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone | Carcinoma of the breast or known or suspected carcinoma of the prostate; Pregnancy or breastfeeding |
| Testosterone | Vogelxo | Gel | Indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone | Carcinoma of the breast or known or suspected carcinoma of the prostate; Pregnancy or breastfeeding |
| Testosterone | Androgel | Gel | Indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone | Carcinoma of the breast or known or suspected carcinoma of the prostate; Pregnancy or breastfeeding; Pregnant women need to be aware of the potential for transfer of testosterone from men |
| Testosterone | Fortesta | Gel | Indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone | Carcinoma of the breast or known or suspected carcinoma of the prostate; Pregnancy or breastfeeding |
| Testosterone | Natesto | Nasal gel | Indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone | Carcinoma of the breast or known or suspected carcinoma of the prostate; Pregnancy or breastfeeding |
| Testosterone | Androderm | Patch | Indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone | Carcinoma of the breast or known or suspected carcinoma of the prostate; Pregnancy or breastfeeding |
| Testosterone | Striant | Tablet (buccal system) | Indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone | Carcinoma of the breast or known or suspected carcinoma of the prostate; Pregnancy or breastfeeding |
| Testosterone | Testopel | Pellet | Indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone | Carcinoma of the breast or known or suspected carcinoma of the prostate; Pregnancy or breastfeeding |
| Testosterone cypionate | DepoTestosterone | Injection | Indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone | Carcinoma of the breast or known or suspected carcinoma of the prostate; Pregnancy or breastfeeding; Known hypersensitivity to the drug; serious cardiac, hepatic, or renal disease |
| Dehydroepiandrosterone (DHEA; also known as Prasterone) | Intrarosa | Vaginal insert | Indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause | Undiagnosed abnormal genital bleeding: Any postmenopausal woman with undiagnosed, persistent, or recurring genital bleeding should be evaluated to determine the cause of the bleeding before consideration of treatment |
